Biotech Stock Gets Jeff Bezos' $130M Backing 🚀

It could be the most explosive trade of the year.                                                                                                                                                                                                                                                                                                                                                                                                                 April 27, 2024 | [Read Online]( [Elite Trade Club] Dear Fellow Investor, [A little-known biotech stock]( has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda. And they have a clean balance sheet with over $1 billion in cash to fund their efforts. Now, investors are [lining up to buy shares](. Stock purchases by institutional buyers more than doubled in the last quarter of 2023. What is it about this stock that has everyone excited? [Find out more here ]( "The Buck Stops Here," Dylan Jovine, CEO & Founder Behind the Markets This is a PAID ADVERTISEMENT provided to subscribers of [EliteTrade.Club](. Although we have sent you this email, EliteTrade.club does NOT specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Update your email preferences or unsubscribe [here]( © 2024 Elite Trade Media LLC 1969 Alafaya Tr., Suite #247 Orlando, Florida 32828, United States of America [[beehiiv logo]Powered by beehiiv](